Canada Oral Thin Films Market Insights Forecasts to 2033

• The Canada Oral Thin Films Market Size was valued at USD 197.5 Million in 2023.
• The Market is Growing at a CAGR of 8.61% from 2023 to 2033
• The Canada Oral Thin Films Market Size is expected to reach USD 448.5 Million by 2033

The Canada Oral Thin Films Market is anticipated to exceed USD 448.5 Million by 2033, growing at a CAGR of 8.61% from 2023 to 2033. The increasing burden of target diseases and advantages associated with thin films are driving the growth of the oral thin films market in Canada.     

Market Overview

Oral thin films (OTFs) are thin films composed of mono or multi-layer polymeric matrix designed to rapidly deliver drugs systemically. They are applied in the mouth, providing fast, local, or systemic effects. The systemic distribution of APIs in over-the-counter (OTC) products is presently accomplished using OTFs, a well-established and popular technology still in its infancy for application in prescription medications. In addition to the buccal technique, fast-dissolving oral thin films are being used for sublingual and gastro-retentive delivery methods. Thus, the growing demand for sublingual films is upsurging the market growth for oral thin films. Children, the elderly, and bedridden patients have trouble swallowing typical oral dosage forms. After effectively overcoming this obstacle, oral thin films (OTFs), often referred to as oral rapid-dissolving films, have gained broad attention.

Report Coverage

This research report categorizes the market for the Canada oral thin films market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Canada oral thin films market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Canada oral thin films market.

Driving Factors

The benefits associated with oral thin films include convenience of use, precise dosing, quick disintegration, and maybe increased patient compliance are responsible for driving the market. Numerous pharmaceutical substances, such as prescription pharmaceuticals, over-the-counter medications, and nutraceuticals, are delivered via oral thin films. Patients with specific disorders—such as schizophrenia, Parkinson's disease, Alzheimer's disease, migraine, and others—are given oral thin films.  

Restraining Factors

The oral thin film transports a relatively limited drug load of 10 to 20 mg compared to the traditional oral drug administration technique and is more susceptible to humidity and temperature. These technical limitations of oral thin films are restraining the Canadian oral thin films market.

Market Segmentation

The Canada Oral Thin Films Market share is classified into product, disease indication, and distribution channel.

• The sublingual films segment dominated the market with the largest market share during the forecast period.

The Canada oral thin films market is segmented by product into sublingual films and others. Among these, the sublingual films segment dominated the market with the largest market share during the forecast period. The sublingual method is intended to administer drugs with high mucosal permeability and is used to treat acute illnesses. To get to the rest of the body, active substances disperse via the floor of the mouth and the underside of the tongue. The increasing preference of medical professionals and patients for faster medication delivery is driving the market in the sublingual films segment.

• The opioid dependence segment dominated the Canada oral thin films market during the forecast period.        

Based on the disease indication, the Canada oral thin films market is divided into opioid dependence, nausea & vomiting, and others. Among these, the opioid dependence segment dominated the Canada oral thin films market during the forecast period. Thin films are versatile platform for drug delivery as it is convenient to swallow, self-administrable, and fast dissolving dosage form. The increasing use of oral thin films for treating opioid addiction is responsible for driving the market in the opioid dependence segment.

• The retail pharmacies segment dominated the Canada oral thin films market during the forecast period.       

The Canada oral thin films market is segmented by distribution channel into hospital pharmacies, retail pharmacies, and others. Among these, the retail pharmacies segment dominated the Canada oral thin films market during the forecast period. Prescriptions are sent to any hospital pharmacy, government pharmacy, or nonprofit institution, and they are meant for direct client use. The increasing prevalence of chronic diseases with increasing demand for home care surge the need for medication leads to drive the market.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Canada oral thin films market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• LTS Lohmann Therapie-Systeme AG
• MonoSol Rx
• Indivior PLC
• Novartis AG
• Pfizer, Inc.
• Tesa Labtec GmbH
• Wolters Kluwer
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In September 2020, IntelGenx inks double deals to develop oral film psychedelics for psychiatric use. Drug delivery specialist IntelGenx has penned two deals to develop film-based, prescription psychedelics amid a surge of interest—and investment—from the biopharma industry.

Market Segment

This study forecasts revenue at Canada, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the Canada Oral Thin Films Market based on the below-mentioned segments:

Canada Oral Thin Films Market, By Product

• Sublingual Films
• Others

Canada Oral Thin Films Market, By Disease Indication

• Opioid Dependence
• Nausea & Vomiting
• Others

Canada Oral Thin Films Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others